title: Cisapride and dexamethasone in the prevention of delayed emesis after cisplatin administration.
abstract: Management of delayed emesis (DE) remains unsatisfactory, and only 50% of the patients achieve complete protection. Cisapride is a strong prokinetic gastrointestinal drug that could have a role in the prevention of DE. We enrolled 31 adult naive outpatients who were scheduled to receive cisplatin chemotherapy at doses of > or = 75 mg/m2. All patients received the same prophylactic treatment for acute emesis (20 mg dexamethasone and 8 mg ondansetron i.v.) and, as preventive therapy for DE, oral cisapride, 10 mg every 8 h on days 2-4, combined with dexamethasone i.m., 8 mg twice daily on days 2 and 3, and 4 mg twice daily on day 4. All patients were evaluable for activity. Complete protection from acute vomiting was 80.7%, from nausea 71% and from nausea/vomiting 64.5%. The overall protection from DE (days 2-4) was 74.1% for vomiting, 64.5% for nausea and 58% for nausea/vomiting. In our study the combination of cisapride and dexamethasone was effective, giving 58% of complete protection from DE, and it is therefore worthy of further studies.
authors.affiliation: IST (Istituto Nazionale per la Ricerca sul Cancro), Genua, Sez. Dec. Messina, Italy. maisano.r@tiscalinet.it
authors.forename: R
authors.initials: R
authors.lastname: Maisano
authors.forename: P
authors.initials: P
authors.lastname: Spadaro
authors.forename: G
authors.initials: G
authors.lastname: Toscano
authors.forename: N
authors.initials: N
authors.lastname: Caristi
authors.forename: S
authors.initials: S
authors.lastname: Pergolizzi
authors.forename: V
authors.initials: V
authors.lastname: Salimbeni
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D020117:Cisapride / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects*; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced* / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D017366:Serotonin Receptor Agonists; D003907:Dexamethasone; D002945:Cisplatin; D020117:Cisapride